(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.48%.
Biohaven's earnings in 2026 is -$780,110,000.On average, 19 Wall Street analysts forecast BHVN's earnings for 2026 to be -$375,881,070, with the lowest BHVN earnings forecast at -$816,418,468, and the highest BHVN earnings forecast at -$221,184,346. On average, 17 Wall Street analysts forecast BHVN's earnings for 2027 to be -$280,876,068, with the lowest BHVN earnings forecast at -$720,979,461, and the highest BHVN earnings forecast at -$147,826,724.
In 2028, BHVN is forecast to generate -$198,150,265 in earnings, with the lowest earnings forecast at -$236,046,410 and the highest earnings forecast at -$160,052,994.